Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.

摘要: Background Generalised anxiety disorder (GAD) has received less study than other disorders, particularly its long-term treatment. Aims To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. Method A total 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind three fixed doses (37.5, 75 150 mg/day) ER. Results All ER showed superior placebo, apparent from week 2, that was sustained throughout 24-week for two higher doses. The discontinuation rate did not differ significantly among treatment groups. Conclusions Venlafaxine is an effective safe GAD up 6 months.